Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
estimated completion

Description

Summary

This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.

Official Title

An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension

Keywords

Open-Angle Glaucoma Ocular Hypertension Glaucoma Glaucoma, Open-Angle Hypertension Bimatoprost Bimatoprost SR Bimatoprost SR 10mcg; Lead-in study 192024-093 Bimatoprost SR 15mcg; Lead-in studies 192024-093/-095 Bimatoprost SR 10mcg; Lead-in studies 192024-091/-092 Bimatoprost SR 15mcg; Lead-in studies 192024-091/-092

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR

You CAN'T join if...

  • Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study
  • Concurrent or anticipated enrollment in another investigational drug or device study during the present study
  • Any condition which would preclude the patient's ability to comply with study requirements, including completion of the study
  • Patients who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092

Locations

  • Hamilton Glaucoma Center, Shiley Eye Center UCSD
    La Jolla California 92037 United States
  • Lakeside Vision Center
    Irvine California 92604 United States
  • Eye Research Foundation
    Newport Beach California 92663 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
ID
NCT03891446
Phase
Phase 3
Study Type
Interventional
Last Updated